CSL Limited (CSLLY)

76.91

+0.47

+(0.61%)

As of 11:23:28 AM EDT. Market Open.

Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

This week’s picks cover: Why Alphabet is the most undervalued Mag7 stock, how PVA TePLa is on the cusp of being re-rated higher, and why CSL is undervalued, no matter how high the tariffs go.

Simply Wall St. 7 days ago

GOOG

CMXHF
+0.22%
CSLLY
+0.61%
Are CSL Limited's (ASX:CSL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

CSL (ASX:CSL) has had a rough three months with its share price down 17%. However, stock prices are usually driven by a...

Simply Wall St. 9 days ago

CMXHF
+0.22%
CSLLY
+0.61%
BMRN vs. CSLLY: Which Stock Is the Better Value Option?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 15 days ago

BMRN

CSL.AX
CSL initiated with an Overweight at Morgan Stanley

Morgan Stanley initiated coverage of CSL (CSLLY) with an Overweight rating and A$313 price target A “solid revenue growth outlook” and margin recovery for CSL Behring underpin group EPS growth of about 13% per year over the next three years, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on CSLLY: Arcturus Therapeutics and CSL’s Kostaive COVID-19 vaccine

TipRanks last month

CMXHF
+0.22%
CSLLY
+0.61%
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks last month

CSL.AX

BMRN
Only Two Days Left To Cash In On CSL's (ASX:CSL) Dividend

CSL Limited ( ASX:CSL ) stock is about to trade ex-dividend in 2 days. The ex-dividend date is usually set to be two...

Simply Wall St. last month

CMXHF
+0.22%
CSLLY
+0.61%
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales –ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia and New Zealand. Under the terms of the agreement, Esperion

GlobeNewswire last month

ESPR

CMXHF
+0.22%
CSLLY
+0.61%
BMRN or CSLLY: Which Is the Better Value Stock Right Now?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks last month

BMRN

CSL.AX
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)

CSL Behring K.K. (Headquarters: Minato-ku, Tokyo; President and Representative Director: Izumi Yoshida) today announced that it has received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens. The product is approved for the prevention of acute attacks of hereditary angioedema (HAE) and is the first pre-filled pen presentation for once-monthly subcutaneous administration for long-ter

PR Newswire 2 months ago

CMXHF
+0.22%
CSLLY
+0.61%
Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results

CSL Limited ( ASX:CSL ) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to AU$257...

Simply Wall St. 2 months ago

CMXHF
+0.22%
CSLLY
+0.61%
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19.

PR Newswire 2 months ago

CMXHF
+0.22%
CSLLY
+0.61%
ARCT
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ANDEMBRY® (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. ANDEMBRY inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body. ANDEMBRY reinforces CSL's decades-long commitment

PR Newswire 2 months ago

CMXHF
+0.22%
CSLLY
+0.61%
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients. The data showed that through four years, Hemgenix continues to deliver elevated and sustained factor IX activity levels, can offer long-term and greater bleed protection compared to prophylactic treatment, can eliminate the need for ro

Benzinga 2 months ago

QURE

CSL.AX
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) for adults living with hemophilia B. In an oral presentation at the 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), data showed that through four years, HEMGENIX continues to deliver elevated and sustained factor I

PR Newswire 2 months ago

CMXHF
+0.22%
CSLLY
+0.61%
QURE
As CSL (ASX:CSL) rises 3.6% this past week, investors may now be noticing the company's five-year earnings growth

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Simply Wall St. 2 months ago

CMXHF
+0.22%
CSLLY
+0.61%
Is CSL Limited (ASX:CSL) Trading At A 30% Discount?

Key Insights CSL's estimated fair value is AU$408 based on 2 Stage Free Cash Flow to Equity CSL is estimated to be 30...

Simply Wall St. 3 months ago

CMXHF
+0.22%
CSLLY
+0.61%
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorization for garadacimab as a once-monthly prophylactic treatment for hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. Garadacimab is a monoclonal antibody that targets activated factor XII (factor XIIa), a plasma protein that plays

PR Newswire 4 months ago

CMXHF
+0.22%
CSLLY
+0.61%
CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform

SAN FRANCISCO, December 09, 2024--In 2023, the life sciences industry experienced a 13% year-over-year increase in digital experiences, outpacing the global average by 5 percentage points, according to the 2024 Life Sciences Digital Engagement Benchmarks Report. This growth reflects the life sciences industry's increasing focus on omnichannel strategies to engage healthcare professionals (HCPs). Today, ON24 (NYSE: ONTF), a leading intelligent engagement platform, announced that CSL Behring, a gl

Business Wire 4 months ago

ONTF

CMXHF
+0.22%
CSLLY
+0.61%
EXEL vs. CSLLY: Which Stock Is the Better Value Option?

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 4 months ago

CSL.AX

EXEL
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 5 months ago

CSL.AX

EXEL

Performance Overview

Return	CSLLY	S&P/ASX 200 [XJO] (^AXJO)
YTD	-12.16%	-2.92%
1-Year	-14.60%	+3.08%
3-Year	-18.14%	+5.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

CSL Limited (CSLLY)

Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

Are CSL Limited's (ASX:CSL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

CSL initiated with an Overweight at Morgan Stanley

BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

Only Two Days Left To Cash In On CSL's (ASX:CSL) Dividend

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

BMRN or CSLLY: Which Is the Better Value Stock Right Now?

CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)

Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

As CSL (ASX:CSL) rises 3.6% this past week, investors may now be noticing the company's five-year earnings growth

Is CSL Limited (ASX:CSL) Trading At A 30% Discount?

CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Performance Overview